Skip to main content

Table 2 Demographics and clinical findings of RA patients

From: Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis

  Derivation (group A) Validation (group B)
n RA n RA
Age (years, mean ± SD) 87 56.1 ± 13.8 88 57.3 ± 14.2
Female (%) 87 64 (73.6) 88 66 (75)
Serology n (%)
 CCP positive 74 52 (70.3) 78 57 (73.1)
 RF positive 82 48 (58.5) 85 53 (62.4)
 CRPb (mg/L) 63 10.91 ± 22.73 74 7.24 ± 11.86
 Tobacco n (%) 85 22 (25.9) 82 19 (23.5)
 Disease duration (years) 88 11.6 ± 5.8 89 10.3 ± 6.1
 Active diseasea n (%) 81 42 (51.9) 82 37 (45.1)
 RAPID-3 scoresc 71 27 (38) 67 24 (35.8)
 Erosions 82 27 (32.9) 84 25 (29.8)
 Subcutaneous nodules 84 11 (13.1) 88 9 (10.2)
 ILDd 87 4 (4.6) 89 3 (3.4)
Current treatment n (%)
 Biologics 86 36 (41.9) 85 33 (38.8)
 DMARDe 85 78 (91.8) 86 78 (90.7)
 Prednisone > 5 mg 85 6 (7.1) 85 7 (8.2)
 Biologics ever 84 42 (50) 85 41 (48.2)
  1. aActive disease: defined as presence of at least one swollen joint
  2. b CRP C-reactive protein, c RAPID routine assessment of patient index data, d ILD interstitial lung disease, e DMARD disease-modifying antirheumatic drug